JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

Pharmacological and Non-Pharmacological Interventions for Improving Quality of Life in Dementia Care

Pravallika Sai Sri R*[1], Sunitha K[2]

[1] *UG Scholar, Department of Pharmaceutical Analysis, Koringa College of Pharmacy, Korangi, Tallarevu, Andhra Pradesh, India*
[2] *Assistant Professor, Department of Pharmaceutical Analysis, Koringa College of Pharmacy, Korangi, Tallarevu, Andhra Pradesh, India*

Publication history: Received on 10th June 2025; Revised on 6th July 2025; Accepted on 20th July 2025

Article DOI: 10.69613/fpnx4k55

Abstract: Dementia is characterized by progressive cognitive decline, behavioral changes, and diminished independence. Current pharmacological interventions, including cholinesterase inhibitors, memantine, and antipsychotics, demonstrate variable efficacy in improving quality of life (QoL) and are often limited by adverse effects. Non-pharmacological interventions (NPIs) are being used as crucial components in dementia management, particularly in residential and community settings. Cognitive stimulation therapy has shown robust evidence for QoL improvement, while physical exercise, reminiscence therapy, music therapy, and cognitive rehabilitation show promising outcomes. Analysis of systematic studies reveals the significance of person-centered care models that combine psychosocial, emotional, and spiritual aspects alongside conventional medical management. Complementary approaches, including occupational therapy, art therapy, and sensory-based interventions, contribute variably to patient well-being. Implementation barriers and methodological limitations in current research necessitate stronger evidence for emerging therapies and development of practical guidelines for translating NPIs into clinical practice. Recent advances in digital biomarkers, artificial intelligence tools, and hybrid care models offer new opportunities for personalizing interventions and monitoring disease progression. The use of pharmacological and non-pharmacological interventions, coupled with early detection strategies and risk management, shows a promising direction for optimizing QoL in dementia care.

Keywords: Dementia; Quality of Life; Cognitive Stimulation Therapy; Person-Centered Care; Behavioral Therapy.

1. Introduction

Dementia manifests as a complex neurological syndrome characterized by progressive deterioration in cognitive function, behavioral patterns, and daily living activities. The global prevalence of dementia has reached critical proportions, with approximately 55 million individuals affected worldwide in 2020, and projections indicating an increase to 139 million by 2050 [1]. The associated economic burden is expected to surpass $2.8 trillion annually by 2030, representing a significant challenge for healthcare systems worldwide [2].

The pathophysiology of dementia encompasses multiple subtypes, including Alzheimer's disease (AD), vascular dementia (VaD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD), each presenting unique challenges in management and care [3]. Traditional approaches have primarily focused on cognitive and functional outcomes, often overlooking the crucial aspect of quality of life (QoL) [4]. Recent paradigm shifts in dementia care emphasize the importance of QoL as a primary endpoint, recognizing its multidimensional nature that extends beyond cognitive function to encompass emotional well-being, social relationships, and functional independence [5].

The World Health Organization's conceptualization of QoL in dementia incorporates both objective and subjective dimensions, including physical health, psychological state, social relationships, and environmental factors [6]. Assessment of QoL in individuals with dementia presents unique challenges, particularly in advanced stages where self-reporting becomes difficult. Validated instruments such as the Quality of Life in Alzheimer's Disease (QoL-AD) scale and DEMQOL have been developed to address these challenges, though discrepancies between self-reported and proxy-reported outcomes remain a significant consideration [7].

Current therapeutic approaches in dementia care can be broadly categorized into pharmacological and non-pharmacological interventions. Pharmacological treatments, including cholinesterase inhibitors (ChEIs) and memantine, have shown modest efficacy in cognitive enhancement but variable impact on overall QoL [8]. The limitations of pharmacological approaches, including adverse effects and incomplete symptom control, have led to increased interest in non-pharmacological interventions (NPIs) [9]

* Corresponding author: Pravallika Sai Sri R

Table 1. Classification and Features of Subtypes of Major Dementia

Type of Dementia	Prevalence (%)	Primary Pathology	Clinical Features	Typical Age of Onset
Alzheimer's Disease	60-70	Amyloid plaques, neurofibrillary tangles	Early memory impairment, language deficits	>65 years
Vascular Dementia	15-20	Cerebrovascular disease	Step-wise progression, focal neurological signs	60-75 years
Lewy Body Dementia	10-15	α-synuclein deposits	Visual hallucinations, parkinsonism	50-85 years
Frontotemporal Dementia	5-10	Tau or TDP-43 protein accumulation	Behavioral changes, language dysfunction	45-65 years
Mixed Dementia	10-15	Multiple pathologies	Mixed clinical features	>65 years

2. Assessment of Quality of Life in Dementia

2.1. Domains

The assessment of QoL in dementia requires a multifaceted approach that considers both objective and subjective indicators [10]. The determination of QoL contains several domains:

2.1.1. Cognitive Function

Cognitive assessment extends beyond traditional memory testing to include executive function, language, and visuospatial abilities. The relationship between cognitive decline and QoL is not linear, with some individuals maintaining good QoL despite significant cognitive impairment [11].



Figure 1. Quality of Life in Dementia

2.1.2. Functional Status

Activities of daily living (ADL) capabilities significantly influence QoL, with both basic ADLs and instrumental ADLs serving as important indicators of independence and well-being [12].

Table 2. Quality of Life Assessment Tools in Dementia

Assessment Tool	Domains Measured	Administration Time	Validity Score‡	Target Population
QoL-AD	13 domains including physical health, mood	10-15 mins	0.88	Mild-moderate dementia
DEMQOL	Cognition, daily activities, relationships	20-30 mins	0.87	All stages
QUALIDEM	Care relationship, affect, social behavior	15-20 mins	0.82	Moderate-severe dementia
EQ-5D-5L	Mobility, self-care, usual activities	5-10 mins	0.79	Mild-moderate dementia
ADRQL	Social interaction, awareness, behavior	20-25 mins	0.85	All stages

‡Validity Score: Internal consistency reliability (Cronbach's α)



Figure 1. Integrated Care in the Management of Dementia

2.1.3. Social Engagement

Social relationships and community participation play crucial roles in maintaining QoL, with evidence suggesting that social isolation accelerates cognitive decline and reduces overall well-being [13].

2.2. Assessment Tools

Contemporary QoL assessment in dementia utilizes various instruments like:

2.2.1. Direct Assessment Tools

The QoL-AD scale remains one of the most widely used instruments, demonstrating good reliability and validity across different dementia stages [14]. The scale incorporates both self-rated and proxy-rated components, providing a comprehensive assessment of 13 domains including physical health, energy, mood, and social relationships [15].

2.2.2. Proxy-Based Measures

For individuals with advanced dementia, proxy-based instruments such as QUALIDEM offer valuable insights into QoL through behavioral observation and caregiver reports [16]. These measures assess domains including care relationship, positive affect, and social isolation [17].

3. Pharmacological Interventions

3.1. Cholinesterase Inhibitors

Cholinesterase inhibitors (ChEIs) represent the primary pharmacological intervention for cognitive symptoms in dementia, particularly in Alzheimer's disease. Three main agents have shown clinical efficacy:

3.1.1. Donepezil

Donepezil, a selective acetylcholinesterase inhibitor, shows consistent benefits in cognitive function and global clinical status [18]. Long-term studies indicate sustained cognitive benefits over 12-24 months, though effects on QoL measures remain variable [19]. The recommended dosing begins at 5 mg daily, with potential escalation to 10 mg daily based on individual response and tolerability [20].

Table 3. Pharmacological Interventions and Their Impact on Quality of Life

Drug Class	Examples	Primary Indication	QoL Impact Score*	Side Effects
Cholinesterase Inhibitors	Donepezil, Rivastigmine	Mild-Moderate AD	++	GI symptoms, bradycardia
NMDA Antagonists	Memantine	Moderate-Severe AD	++	Dizziness, confusion
Antipsychotics	Risperidone, Quetiapine	BPSD**	+	Increased mortality risk
Antidepressants	Sertraline, Citalopram	Depression in dementia	++	GI symptoms, hyponatremia

*QoL Impact Score: +++ (strong positive), ++ (moderate positive), + (mild positive)
**BPSD: Behavioral and Psychological Symptoms of Dementia

3.1.2. Rivastigmine

Rivastigmine, a dual inhibitor of acetylcholinesterase and butyrylcholinesterase, demonstrates particular efficacy in patients with concurrent Parkinson's disease dementia [21]. The transdermal formulation offers advantages in terms of gastrointestinal tolerability and adherence. Initial dosing starts at 1.5 mg twice daily, with gradual titration to an optimal maintenance dose of 6 mg twice daily [22].

3.1.3. Galantamine

Galantamine combines cholinesterase inhibition with allosteric modulation of nicotinic receptors, potentially offering additional benefits in attention and executive function [23]. Clinical trials demonstrate significant improvements in cognitive and functional measures, with optimal dosing ranging from 16-24 mg daily in divided doses [24].

3.2. N-Methyl-D-Aspartate (NMDA) Receptor Antagonists

3.2.1. Memantine

Memantine acts through modulation of glutamatergic neurotransmission, showing particular efficacy in moderate to severe dementia [25]. The drug demonstrates significant benefits in cognitive function, behavior, and activities of daily living, with evidence suggesting enhanced effects when combined with cholinesterase inhibitors [26]. Standard dosing involves gradual titration from 5 mg daily to a target dose of 20 mg daily [27].

3.3. Management of Behavioral and Psychological Symptoms

3.3.1. Antipsychotics

Second-generation antipsychotics play a limited role in managing severe behavioral symptoms, though their use requires careful consideration of risk-benefit ratios [28]. Clinical evidence supports short-term use of risperidone and aripiprazole for severe agitation and aggression, with close monitoring for adverse effects including cerebrovascular events and increased mortality [29].

3.3.2. Antidepressants

Selective serotonin reuptake inhibitors (SSRIs) demonstrate efficacy in managing depression and anxiety in dementia patients [30]. Sertraline and citalopram show particular promise in reducing agitation and aggression, with potentially better safety profiles compared to antipsychotics [31].

3.4. Disease-Modifying Therapies

Recent developments in monoclonal antibodies targeting amyloid-β, including aducanumab and lecanemab, represent potential advances in modifying disease progression [32]. These agents demonstrate variable effects on cognitive outcomes and require careful patient selection and monitoring [33].

3.5. Combination Therapy

Emerging evidence supports the use of combination approaches, particularly the concurrent administration of cholinesterase inhibitors and memantine in moderate to severe dementia [34]. Such combinations may offer synergistic benefits in cognitive function and daily activities [35].

4. Non-Pharmacological Interventions

4.1. Cognitive-Based Interventions

4.1.1. Cognitive Stimulation Therapy (CST)

CST represents a structured group intervention targeting multiple cognitive domains through themed activities and social interaction [36]. Standard protocols typically involve twice-weekly sessions over 7-14 weeks, focusing on orientation, categorization, and practical problem-solving tasks [37]. Neuroimaging studies demonstrate increased activation in frontotemporal regions and enhanced functional connectivity following CST interventions [38].

4.1.2. Cognitive Rehabilitation

Individualized cognitive rehabilitation focuses on personally relevant goals and daily functioning [39]. The approach employs compensatory strategies and environmental modifications to support specific functional tasks. Evidence indicates particular efficacy in early-stage dementia and mild cognitive impairment, with sustained benefits in targeted activities up to 6 months post-intervention [40].

4.1.3. Reality Orientation

This approach combines environmental modifications with systematic presentation of orientation information [41]. Contemporary applications integrate digital aids and environmental cues to reinforce temporal and spatial awareness, showing particular benefit in residential care settings [42].

4.2. Physical Activity

4.2.1. Structured Exercise Programs

Systematic analysis of exercise interventions reveals optimal benefits from multicomponent programs combining aerobic activity, strength training, and balance exercises [43]. Programs typically recommend 150 minutes of moderate-intensity activity per week, adapted to individual capabilities and risk factors [44].

4.2.2. Adapted Physical Activities

Specialized interventions such as chair-based exercises and tai chi demonstrate particular benefits in balance, fall prevention, and maintenance of functional mobility [45]. Water-based exercises show promise in reducing behavioral symptoms and improving sleep patterns [46].

Table 4. Evidence-Based Non-Pharmacological Interventions

Intervention Type	Session Duration	Frequency	Effect Size†	Primary Outcomes
Cognitive Stimulation	45-60 mins	2x/week	0.41	Cognition, social interaction
Physical Exercise	30-45 mins	3x/week	0.37	Physical function, mood
Music Therapy	30-60 mins	2x/week	0.39	Behavior, engagement
Reminiscence Therapy	45-60 mins	1x/week	0.33	Mood, communication
Art Therapy	45-60 mins	1x/week	0.28	Expression, well-being

†Effect sizes reported as standardized mean differences from meta-analyses

4.3. Psychosocial Interventions

4.3.1. Reminiscence Therapy

Structured reminiscence interventions utilize personal memories and life experiences to enhance mood and social engagement [47]. Digital platforms and multimedia approaches have expanded traditional reminiscence methods, allowing for more personalized and accessible interventions [48].

4.3.2. Music Therapy

Music-based interventions demonstrate significant effects on mood, behavior, and social interaction [49]. Protocols incorporate both receptive (listening) and active (participation) components, with evidence suggesting particular benefits from familiar music and rhythmic activities [50].

4.3.3. Art Therapy

Visual art interventions promote creative expression and sensory stimulation while providing opportunities for social interaction [51]. Structured programs in museum settings demonstrate benefits in mood, engagement, and caregiver relationships [52].

4.4. Environmental Interventions

4.4.1. Physical Environment Modifications

Evidence-based design principles emphasize clear wayfinding, appropriate lighting, and controlled acoustic environments [53]. Specific modifications include:

- Color contrast and environmental cues for spatial orientation
- Adequate lighting to minimize shadowing and glare
- Acoustic treatments to reduce background noise and enhance communication
- Safe wandering paths and meaningful activity stations [54]

4.4.2. Sensory Interventions

Multisensory stimulation environments (Snoezelen) provide controlled sensory experiences through light, sound, texture, and aromatherapy [55]. Targeted sensory interventions demonstrate particular efficacy in reducing agitation and improving mood in moderate to severe dementia [56].

5. Conclusion

The management of dementia consists of both pharmacological and non-pharmacological interventions to optimize quality of life. While cholinesterase inhibitors and memantine remain cornerstone pharmacological treatments, their modest efficacy indicate the critical role of complementary non-pharmacological interventions. Cognitive stimulation therapy is the found to be best among non-pharmacological interventions, particularly when delivered through structured group programs. Physical exercise, reminiscence therapy, and music-based interventions show promising outcomes in maintaining functional abilities and reducing behavioral symptoms. The evolution of person-centered care models acknowledges the unique needs and preferences of individuals with dementia, moving beyond traditional symptom-focused approaches. Environmental modifications and sensory interventions provide additional therapeutic opportunities, particularly in residential care settings. Digital technologies and artificial intelligence tools offer new possibilities for personalizing interventions and monitoring disease progression. Success in optimizing quality of life for individuals with dementia ultimately depends on coordinated efforts across healthcare systems, supported by evidence-based guidelines and sustainable implementation models.

References

[1] GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105-e125.

[2] Wimo A, Guerchet M, Ali GC, Wu YT, Prina AM, Winblad B, et al. The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement. 2017;13(1):1-7.

[3] Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-446.

[4] Martyr A, Nelis SM, Quinn C, Wu YT, Lamont RA, Henderson C, et al. Living well with dementia: a systematic review and correlational meta-analysis of factors associated with quality of life, well-being and life satisfaction in people with dementia. Psychol Med. 2018;48(13):2130-2139.

[5] Dichter MN, Quasdorf T, Schwab CG, Trutschel D, Haastert B, Riesner C, et al. Dementia care mapping: effects on residents' quality of life and challenging behavior in German nursing homes. A quasi-experimental trial. Int Psychogeriatr. 2015;27(11):1875-1892.

[6] World Health Organization. Global action plan on the public health response to dementia 2017-2025. Geneva: WHO; 2017.

[7] Bowling A, Rowe G, Adams S, Sands P, Samsi K, Crane M, et al. Quality of life in dementia: a systematically conducted narrative review of dementia-specific measurement scales. Aging Ment Health. 2015;19(1):13-31.

[8] Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2018;6(6):CD001190.

[9] O'Brien JT, Holmes C, Jones M, Jones R, Livingston G, McKeith I, et al. Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2017;31(2):147-168.

[10] Missotten P, Dupuis G, Adam S. Dementia-specific quality of life instruments: a conceptual analysis. Int Psychogeriatr. 2016;28(8):1245-1262.

[11] Martyr A, Clare L. Executive function and activities of daily living in Alzheimer's disease: a correlational meta-analysis. Dement Geriatr Cogn Disord. 2012;33(2-3):189-203.

[12] Giebel CM, Sutcliffe C, Challis D. Activities of daily living and quality of life across different stages of dementia: a UK study. Aging Ment Health. 2015;19(1):63-71.

[13] Kuiper JS, Zuidersma M, Oude Voshaar RC, Zuidema SU, van den Heuvel ER, Stolk RP, et al. Social relationships and risk of dementia: A systematic review and meta-analysis of longitudinal cohort studies. Ageing Res Rev. 2015;22:39-57.

[14] Logsdon RG, Gibbons LE, McCurry SM, Teri L. Quality of life in Alzheimer's disease: Patient and caregiver reports. J Ment Health Aging. 1999;5:21-32.

[15] Orgeta V, Edwards RT, Hounsome B, Orrell M, Woods B. The use of the EQ-5D as a measure of health-related quality of life in people with dementia and their carers. Qual Life Res. 2015;24(2):315-324.

[16] Ettema TP, Dröes RM, de Lange J, Mellenbergh GJ, Ribbe MW. QUALIDEM: development and evaluation of a dementia specific quality of life instrument. Scalability, reliability and internal structure. Int J Geriatr Psychiatry. 2007;22(6):549-556.

[17] Chua KC, Brown A, Little R, Matthews D, Morton L, Loftus V, et al. Quality-of-life assessment in dementia: the use of DEMQOL and DEMQOL-Proxy total scores. Qual Life Res. 2016;25(12):3107-3118.

[18] Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med. 1998;158(9):1021-1031.

[19] Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med. 2012;366(10):893-903.

[20] Birks JS, Grimley Evans J. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2015;(4):CD001191.

[21] Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004;351(24):2509-2518.

[22] Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007;22(5):456-467.

[23] Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000;54(12):2261-2268.

[24] Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ. 2000;321(7274):1445-1449.

[25] McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019;3(3):CD003154.

[26] Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317-324.

[27] Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348(14):1333-1341.

[28] Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1):CD003476.

[29] Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191-210.

[30] Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682-691.

[31] Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;(2):CD008191.

[32] Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016;537(7618):50-56.

[33] van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9-21.

[34] Grossberg GT, Manes F, Allegri RF, Gutiérrez-Robledo LM, Gloger S, Xie L, et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs. 2013;27(6):469-478.

[35] Spector A, Thorgrimsen L, Woods B, Royan L, Davies S, Butterworth M, et al. Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial. Br J Psychiatry. 2003;183:248-254.

[36] Aguirre E, Woods RT, Spector A, Orrell M. Cognitive stimulation for dementia: a systematic review of the evidence of effectiveness from randomised controlled trials. Ageing Res Rev. 2013;12(1):253-262.

[37] Woods B, Aguirre E, Spector AE, Orrell M. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database Syst Rev. 2012;(2):CD005562.

[38] Clare L, Woods RT, Moniz Cook ED, Orrell M, Spector A. Cognitive rehabilitation and cognitive training for early-stage Alzheimer's disease and vascular dementia. Cochrane Database Syst Rev. 2003;(4):CD003260.

[39] Forbes D, Forbes SC, Blake CM, Thiessen EJ, Forbes S. Exercise programs for people with dementia. Cochrane Database Syst Rev. 2015;(4):CD006489.

[40] Livingston G, Kelly L, Lewis-Holmes E, Baio G, Morris S, Patel N, et al. Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. Br J Psychiatry. 2014;205(6):436-442.

[41] Woods B, O'Philbin L, Farrell EM, Spector AE, Orrell M. Reminiscence therapy for dementia. Cochrane Database Syst Rev. 2018;3(3):CD001120.

[42] Kasl-Godley J, Gatz M. Psychosocial interventions for individuals with dementia: an integration of theory, therapy, and a clinical understanding of dementia. Clin Psychol Rev. 2000;20(6):755-782.

[43] Groot C, Hooghiemstra AM, Raijmakers PG, van Berckel BN, Scheltens P, Scherder EJ, et al. The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials. Ageing Res Rev. 2016;25:13-23.

[44] Brett L, Traynor V, Stapley P. Effects of physical exercise on health and well-being of individuals living with a dementia in nursing homes: a systematic review. J Am Med Dir Assoc. 2016;17(2):104-116.

[45] van der Steen JT, Smaling HJ, van der Wouden JC, Bruinsma MS, Scholten RJ, Vink AC. Music-based therapeutic interventions for people with dementia. Cochrane Database Syst Rev. 2018;7(7):CD003477.

[46] McDermott O, Crellin N, Ridder HM, Orrell M. Music therapy in dementia: a narrative synthesis systematic review. Int J Geriatr Psychiatry. 2013;28(8):781-794.

[47] Deshmukh SR, Holmes J, Cardno A. Art therapy for people with dementia. Cochrane Database Syst Rev. 2018;9(9):CD011073.

[48] Beard RL. Art therapies and dementia care: a systematic review. Dementia. 2012;11(5):633-656.

[49] Fleming R, Crookes PA, Sum S. A review of the empirical literature on the design of physical environments for people with dementia. Primary Dementia Collaborative Research Centre, UNSW; 2008.

[50] Day K, Carreon D, Stump C. The therapeutic design of environments for people with dementia: a review of the empirical research. Gerontologist. 2000;40(4):397-416.

[51] Sánchez A, Millán-Calenti JC, Lorenzo-López L, Maseda A. Multisensory stimulation for people with dementia: a review of the literature. Am J Alzheimers Dis Other Demen. 2013;28(1):7-14.

[52] Strøm BS, Ytrehus S, Grov EK. Sensory stimulation for persons with dementia: a review of the literature. J Clin Nurs. 2016;25(13-14):1805-1834.

[53] van der Ploeg ES, Eppingstall B, Camp CJ, Runci SJ, Taffe J, O'Connor DW. A randomized crossover trial to study the effect of personalized, one-to-one interaction using Montessori-based activities on agitation, affect, and engagement in nursing home residents with dementia. Int Psychogeriatr. 2013;25(4):565-575.

[54] Marquardt G, Bueter K, Motzek T. Impact of the design of the built environment on people with dementia: an evidence-based review. HERD. 2014;8(1):127-157.

[55] Cohen-Mansfield J, Dakheel-Ali M, Marx MS, Thein K, Regier NG. Which unmet needs contribute to behavior problems in persons with advanced dementia? Psychiatry Res. 2015;228(1):59-64.

[56] Scales K, Zimmerman S, Miller SJ. Evidence-Based Nonpharmacological Practices to Address Behavioral and Psychological Symptoms of Dementia. Gerontologist. 2018;58(suppl_1):S88-S102.